Tagged with china

China Top recent news from Chinese pharma, including listings on the Hong Kong Stock Exchange, Junshi’s out-licensing of a potential COVID-19 treatment to Lilly, and Ascentage being granted US FDA orphan drug status for its leukaemia candidate.   Hong Kong IPOs Pick Up the Pace as China Restarts https://www.bloombergquint.com/onweb/hong-kong-ipos-pick-up-the-pace-as-china-restarts-ecm-watch Initial public…

China A selection of recent big stories from Chinese pharma, including Novo Nordisk’s updated China strategy, Chinese biotechs’ funding successes, and some significant regulatory approvals.   In Q1 2020, China’s regulator the National Medical Products Administration (NMPA) approved a total of 11 new drugs, 6 imported and 5 domestic Made with Visme…

China I-Mab Biopharma CFO Jielun Zhu recaps the exciting milestones for the company over the past year since our last interview in May 2019, including most notably their NASDAQ IPO in January 2020, as well as shares some insights on the NASDAQ IPO experience.   Before the IPO, we might have…

Coronavirus With the global coronavirus pandemic still ongoing and teleworking having become the new normal, pharma executives from across the world are giving us their insights into how they are managing in the age of confinement to ensure continued employee welfare and the safe supply of medications to the patients and…

China PharmaBoardroom caught up with Dr Jingsong Wang, chairman & CEO of Harbour BioMed to discuss the exciting clinical and commercial milestones of the prolific biotech in the last year since we last met them in January 2019, including their March USD 75 million Series B+ fundraising round and their preparations…

Opinion Song Ruilin, chairman of the China Pharmaceutical Innovation and Research Development Association (PhIRDA) highlights the leaps and bounds with which the Chinese pharmaceutical industry has developed in recent years, the country’s increasingly important role in the global innovation landscape, and why cross-border collaboration is more crucial than ever in the…

Coronavirus During a global virtual press briefing on 19 March 2020, the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) gathered five global pharmaceutical leaders including Roche Chairman and CEO Severin Schwan to discuss the global ramifications of the COVID-19 crisis.   With Roche’s global leadership in diagnostics, many of the questions…

Coronavirus Over the past few years, innovative Swiss giant Roche has combined its position as the world’s number 1 biotech company and its strength in in vitro diagnostics to brand itself as the frontrunner in personalized healthcare. In 2012, CEO Severin Schwan set the ambitious target of pairing more than 60…

Coronavirus Chinese biotech Clover Biopharmaceuticals may have flown under the radar thus far but it has stepped into the global limelight recently by partnering with GSK to develop a vaccine from the novel coronavirus, COVID-19, now wreaking havoc around the world. But who exactly are the brains behind Clover Biopharmaceuticals and…

China 2019 was a landmark year for the Chinese healthcare industry.* Since the publication of the ‘Healthy China 2030’ blueprint in 2016 by the Chinese government, the entire sector has been virtually turned upside down. Against the warm backdrop of regulatory support, a series of policy changes were unveiled in the…

China Bing Xu, GM of Vital River Laboratories, shares the company’s development in the last 20 years; the challenges of advantages of their JV with Charles River Laboratories; the importance of lab animals for the research & development of new drugs and therapies; their core capabilities and competitive advantage as the…

Coronavirus The ongoing coronavirus outbreak and the subsequent shutdown of factories in China is having severe repercussions for Indian pharma manufacturers and could lead to global shortages.   Shortages and Price Rises in India India depends on China for 80 percent of the Active Pharmaceutical Ingredients (APIs) that it uses in…